What we should learn from the London Olympics

M. Bonini, C. Bachert, C.E. Baena-Cagnani, A. Bedbrook, J.L. Brozek, G.W. Canonica, A.A. Cruz, W.J. Fokkens, R. Gerth van Wijk, L. Grouse, P.W. Hellings, P. Howarth, O. Kalayci, N. Khaltaev, P. Kuna, D. Larenas Linnemann, K. Nekam, S. Palkonen, N.G. Papadopoulos, T.A. PopovD. Price, J. Rosado Pinto, G. Rasi, D. Ryan, B. Samolinski, G.K. Scadding, H.J. Schünemann, D.M. Thomas, M. Triggiani, A. Yorgancioglu, O.M. Yusuf, T. Zuberbier, R. Pawankar, J. Bousquet, S. Bonini, ARIA Initiative, in collaboration with the WHO Collaborating Center for Asthma, Rhinitis

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


The London Olympics have just finished. Official reports will soon become available on how many athletes participating in the games had asthma. However, as in the past [1], prevalence data will often be deducted by the number of athletes using inhaled beta-2 agonists that, according to the new 2012 World Anti-Doping Agency (WADA) rules [2▪], were on this occasion permitted for all the most commonly used short-acting and long-acting drugs, just following a declaration of use made by the athletes themselves. This self-reporting will largely influence the accuracy of estimates, which will not distinguish between clinical asthma and exercise-induced bronchoconstriction (EIB) without clinical asthma, as recently requested.
Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalCurrent Opinion in Allergy and Clinical Immunology
Issue number1
Publication statusPublished - Feb 2013


Dive into the research topics of 'What we should learn from the London Olympics'. Together they form a unique fingerprint.

Cite this